1. Home
  2. Research
  3. Research Groups
  4. Surgical research in urology and renal trasplantation

Surgical research in urology and renal trasplantation

Search for publications

Only original articles, editorials, guidelines.

  • Scilipoti P, Longoni M, de Angelis M, Zaurito P, Slusarczyk A, Soria F, Pradere B, Krajewski W, D'Andrea D, Mari A, Del Giudice F, Pichler R, Subiela JD, Marcq G, Gallioli A, Afferi L, Mastroianni R, Simone G, Albisinni S, Mertens LS, Laukhtina E, Oberneder K, Rodríguez Elena JL, Aranda J, Puentedura AL, Caño Velasco J, Contieri R, Hurle R, Mori K, Radziszewski P, Shariat SF, Gontero P, Necchi A, Rouprêt M, Montorsi F, Salonia A, Briganti A, Moschini M.

    Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer.

    BJU INTERNATIONAL . 136(1): 47-54.

    [doi:10.1111/bju.16675]

  • Carnero-Alcázar M, Nuñez-Gil IJ, Vilacosta I, Montero L, Cuerpo G, Lopez-Menendez J, Feltes-Guzman G, Beltrao-Sial R, Pérez-Camargo D, Vicedo-López Á, Miranda-Torrón J, Solís-Chávez MB, Cobiella J, Maroto L.

    Need for a permanent pacemaker after transcatheter aortic valve implantation in Spain: a retrospective analysis of the national Minimum Basic Dataset from 2017 to 2022.

    Open Heart . 12(1): .

    [doi:10.1136/openhrt-2025-003396]

  • Pichler R, van Creij NCH, Subiela JD, Cimadamore A, Caño-Velasco J, Tully KH, Mori K, Contieri R, Afferi L, Mari A, Soria F, Del Giudice F, D'Elia C, Mayr R, Mertens LS, Pyrgidis N, Moschini M, Gallioli A.

    Biological and therapeutic implications of FGFR alterations in urothelial cancer: A systematic review from non-muscle-invasive to metastatic disease.

    Actas Urologicas Espanolas . 49(5): 501719-501719.

    [doi:10.1016/j.acuroe.2025.501719]

  • Scilipoti P, Longoni M, de Angelis M, Zaurito P, Massiet A, Dutto D, Soria F, Álvarez-Maestro M, Bazán AA, Pradere B, Klatte T, Contieri R, Hurle R, Krajewski W, Subiela JD, Pichler R, Szostek A, Marcq G, Elena JLR, Aranda J, Gontero P, Rouprêt M, Shariat SF, Necchi A, Montorsi F, Briganti A, Xylinas E, Moschini M.

    Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results.

    BJU INTERNATIONAL . 135(6): 969-976.

    [doi:10.1111/bju.16645]

  • Albers Acosta E, Pelari-Mici L, Celada Luis G, Velasco Balanza C, Zapatero A, Romero-Laorden N, Toquero Diez P, Caño-Velasco J, Guerrero-Ramos F, Moschini M, Krajewski W, Del Giudice F, Soria F, Laukhtina E, Mertens L, Pichler R, Mori K, D'Andrea D, Mari A, Marcq G, Teoh J, Afferi L, Albisinni S, Pradere B, Gallioli A, Subiela JD, San José Manso L.

    The impact of a multidisciplinary approach on treatment decisions and outcomes in urothelial carcinoma: A systematic review.

    Actas Urologicas Espanolas . 49(5): 501718-501718.

    [doi:10.1016/j.acuroe.2025.501718]

  • Gómez Rivas J, de la Parra I, Infante S, Ibañez L, Gutierrez Hidalgo B, Cabrera MN, Puente J, Sanmamed N, Ortega Polledo LE, Galante MI, Moreno Sierra J.

    Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) in Initial Staging of Prostate Cancer Patients: The Beginning of a New Era.

    MEDICINA-LITHUANIA . 61(5): .

    [doi:10.3390/medicina61050924]

  • Rodríguez-Moreno JF, de Velasco G, Álvarez-Fernández C, Collado R, Fernández R, Vázquez S, Virizuela JA, Gajate P, Font A, Lainez N, Sevillano-Fernández E, Graña-Castro O, Beltrán L, Madurga R, Rodríguez-Antona C, Berraondo P, Ruiz-Llorente S, García-Donas J.

    Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial.

    CLINICAL CANCER RESEARCH . 31(9): 1644-1656.

    [doi:10.1158/1078-0432.CCR-24-2890]

  • Laszkiewicz J, Del Giudice F, Li S, Krajewski W, Nowak L, Szydelko T, Basran S, De Berardinis E, Carino D, Corvino R, Santerelli V, Ferro M, Rocco B, Sighinolfi MC, Crocetto F, Barone B, Dinacci F, Pichler R, Subiela JD, Pradere B, Moschini M, Mari A, Gallioli A, Mori K, Soria F, Mertens L, Abu-Ghanem Y, Nair R, Khan MS, Chung BI.

    Novel risk factors for venous thromboembolism following outpatient or inpatient transurethral resection of bladder tumors: Multivariable stepwise and LASSO regression modeling from us insurance claim database.

    Actas Urologicas Espanolas . 49(4): 501738-501738.

    [doi:10.1016/j.acuroe.2025.501738]

  • Rivero Belenchón I, Congregado Ruíz CB, Gómez Ciriza G, Gómez Dos Santos V, Burgos Revilla FJ, Medina López RA.

    Impact of 3D-Printed Models for Surgical Planning in Renal Cell Carcinoma With Venous Tumor Thrombus: A Randomized Multicenter Clinical Trial.

    JOURNAL OF UROLOGY . 213(5): 568-580.

    [doi:10.1097/JU.0000000000004425]

  • Artero Fullana S, Caño Velasco J, Lafuente Puentedura A, Polanco Pujol L, Bataller Monfort V, Moralejo Gárate M, Subiela JD, Gallioli A, Moschini M, Pichler R, Del Giudice F, Marcq G, Teoh J, Soria F, Mertens L, Krajewski W, Laukhtina E, Mori K, Pradere B, Afferi L, Tully KH, Albisinni S, Abu Ghanem Y, d'Andrea D, Mari A, Albers Acosta E, Contieri R, Cimadamore A, Grobet-Jeandin E, Gómez Rivas J, Hernández Fernández C.

    Diagnostic accuracy of Bladder EpiCheck for upper tract urothelial carcinoma: A meta-analysis.

    Actas Urologicas Espanolas . 49(4): 501720-501720.

    [doi:10.1016/j.acuroe.2025.501720]

  • Capdevila J, Pubul V, Anido U, Walter T, Molina-Cerrillo J, Alonso-Gordoa T, Garcia-Carbonero R, San-Roman-Gil M, Llana B, Jimenez-Fonseca P, Benavent Viñuales M, Ansquer C, Baudin E, Lepage C, Del Olmo-García M, Ruffinelli JC, Beron A, Haissaguerre M, Deshayes E, Taïeb D, Baldari S, Sansovini M, Cingarlini S, Filice A, Panzuto F, Álvarez-Álvarez R, Lousberg L, Aboubakar Nana F, Hernando J, García-Álvarez A, García-Burillo A, Villacampa G, Vandamme T, Fazio N, Durand A.

    A Randomized clinical trial evaluating the impact on survival and quality of life of (177)Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).

    Bmc Cancer . 25(1): 613-613.

    [doi:10.1186/s12885-025-13941-3]

  • Pal SK, Powles T, Kanesvaran R, Molina-Cerrillo J, Feldman DR, Barata P, Liu M, Bhatt A, Wang Z, Nandoskar P, Suarez C.

    STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma.

    FUTURE ONCOLOGY . 21(7): 1-8.

    [doi:10.1080/14796694.2025.2458395]

  • Fiala O, Buti S, Fujita K, de Liaño AG, Fukuokaya W, Kimura T, Yanagisawa T, Giannatempo P, Angel M, Mennitto A, Molina-Cerrillo J, Bourlon MT, Soares A, Takeshita H, Calabrò F, Ortega C, Kucharz J, Milella M, Seront E, Park SH, Tural D, Benedetti G, Ürün Y, Battelli N, Melichar B, Poprach A, Buchler T, Kopecký J, Conteduca V, Monteiro FSM, Massari F, Gupta S, Santoni M.

    Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2(EV) study.

    CLINICAL & EXPERIMENTAL METASTASIS . 42(2): 18-18.

    [doi:10.1007/s10585-025-10335-4]

  • Del Olmo-García M, Hernandez-Rienda L, Garcia-Carbonero R, Hernando J, Custodio A, Anton-Pascual B, Gomez M, Palma Milla S, Suarez L, Bellver M, Alonso V, Serrano R, Valdés N, Melian M, Febrero B, Sampedro-Nuñez MA, Biarnes J, Díaz-Pérez JÁ, Molina-Cerrillo J, Lopez C, Martínez Olmos MÁ, Merino-Torres JF, Capdevila J, Argente Pla M.

    Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: the NUTRIGETNE (GETNE-S2109) study.

    ONCOLOGIST . 30(2): .

    [doi:10.1093/oncolo/oyae343]

  • Artiles Medina A, Subiela JD, Tagalos Muñoz A, Tato Díez M, Mínguez Ojeda C, López Curtis D, Sánchez González Á, Brasero Burgos J, Serna-Céspedes A, Gómez Dos Santos V, Jiménez Cidre MÁ, Burgos Revilla FJ.

    Clinical outcomes of BCG infections in patients undergoing intravesical immunotherapy for non-muscle-invasive bladder cancer: a systematic review and meta-analysis.

    Minerva Urology And Nephrology . 77(1): 13-24.

    [doi:10.23736/S2724-6051.24.05910-X]

  • Rizzo M, Morelli F, Ürün Y, Buti S, Park SH, Bourlon MT, Grande E, Massari F, Landmesser J, Poprach A, Takeshita H, Roviello G, Myint ZW, Popovic L, Soares A, Abahssain H, Giannatempo P, Molina-Cerrillo J, Incorvaia L, Salah S, Zeppellini A, Monteiro FSM, Porta C, Gupta S, Santoni M.

    Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience.

    CANCER MEDICINE . 14(4): .

    [doi:10.1002/cam4.70479]

  • Tresh AS, Del Giudice F, Li S, Basran S, De Berardinis E, Carino D, Santarelli V, Rocco B, Shighinolfi MC, Mayr R, Ferro M, Autorino R, Bignante G, Crocetto F, Barone B, Pichler R, Subiela JD, Velasco JC, Moschini M, Mari A, Gallioli A, Soria F, Albisinni S, Krajewski W, Laszkiewicz J, Nowak L, Szydelko T, Challacombe B, Nair R, Chung BI.

    The impact of preoperative venous thromboembolism on patients undergoing TURBT: Perioperative outcomes and healthcare costs from US insurance claims data.

    Bjui Compass . 6(1): .

    [doi:10.1002/bco2.481]

  • Rodríguez-Monsalve M, Durán-Poveda M, Gómez Dos Santos V, Burgos Revilla J, García-Criado E, Prieto D, Gil de Miguel Á, Sáenz-Medina J.

    Impact of Obesity on Hospitalization Burden of Urolithiasis in Spain Between 1997 and 2021.

    Journal Of Clinical Medicine . 14(2): .

    [doi:10.3390/jcm14020381]